Literature DB >> 23444345

Intellectual and academic outcome following two chemotherapy regimens and radiotherapy for average-risk medulloblastoma: COG A9961.

M Douglas Ris1, Karin Walsh, Dana Wallace, F Daniel Armstrong, Emi Holmes, Amar Gajjar, Tianni Zhou, Roger J Packer.   

Abstract

PURPOSE: Assess the intellectual and academic outcomes as well as risk factors associated with treatment for average-risk medulloblastoma in childhood using 23.4 Gy of craniospinal radiotherapy plus adjuvant chemotherapy.
METHODS: From an overall sample of 379 enrolled in the parent study (COG A9961), 110 patients received a total of 192 assessments over more than 5 years with standardized IQ and academic achievement tests. Random coefficient models of the various outcomes were developed that incorporated covariates including chemotherapy regimen, age at diagnosis, sex, initial Full Scale IQ, and mutism.
RESULTS: Participants in this study were found to be comparable to the overall sample in all demographic, disease, and treatment factors, except there were more gross total resections in the subsample undergoing intellectual and academic assessment. Major findings include significant decline in both intellectual and academic domains over time that were greater in children who were younger at diagnosis and had higher initial intelligence test scores. Children with mutism were at higher risk for initial effects on intelligence. No effects of sex were found.
CONCLUSION: These results show progressive decline over several years post-treatment in standardized intellectual and academic scores. Despite recent improvements in therapies for these children, most notably a decrease dose of craniospinal radiation, they remain at risk. The pursuit of less toxic treatments, particularly for younger children, should continue. Neuropsychological surveillance should be routine at centers treating children with brain tumors.
Copyright © 2013 Wiley Periodicals, Inc.

Entities:  

Mesh:

Year:  2013        PMID: 23444345      PMCID: PMC6487237          DOI: 10.1002/pbc.24496

Source DB:  PubMed          Journal:  Pediatr Blood Cancer        ISSN: 1545-5009            Impact factor:   3.167


  27 in total

1.  Long-term neuropsychological follow-up of young children with medulloblastoma treated with sequential high-dose chemotherapy and irradiation sparing approach.

Authors:  Taryn B Fay-McClymont; Danielle M Ploetz; Don Mabbott; Karin Walsh; Amy Smith; Susan N Chi; Elizabeth Wells; Jennifer Madden; Ashley Margol; Jonathan Finlay; Mark W Kieran; Douglas Strother; Girish Dhall; Roger J Packer; Nicholas K Foreman; E Bouffet; Lucie Lafay-Cousin
Journal:  J Neurooncol       Date:  2017-04-12       Impact factor: 4.130

2.  Neuropsychological and socioeconomic outcomes in adult survivors of pediatric low-grade glioma.

Authors:  M Douglas Ris; Wendy M Leisenring; Pamela Goodman; Chongzhi Di; Jennie Noll; Wendy Levy; Leslie L Robison; Gregory T Armstrong
Journal:  Cancer       Date:  2019-06-24       Impact factor: 6.860

3.  High expression of the transcriptional coactivator TAZ is associated with a worse prognosis and affects cell proliferation in patients with medulloblastoma.

Authors:  Hao Wang; Ji Zhou; Dong Yang; Liang Yi; Xuhui Wang; Yangqing Ou; Donghong Yang; Lunshan Xu; Minhui Xu
Journal:  Oncol Lett       Date:  2019-09-11       Impact factor: 2.967

4.  Dasatinib suppression of medulloblastoma survival and migration is markedly enhanced by combining treatment with the aurora kinase inhibitor AT9283.

Authors:  William Petersen; Jingbo Liu; Liangping Yuan; Hongying Zhang; Matthew Schneiderjan; Yoon-Jae Cho; Tobey J MacDonald
Journal:  Cancer Lett       Date:  2014-08-10       Impact factor: 8.679

Review 5.  Neurocognitive Outcomes and Interventions in Long-Term Survivors of Childhood Cancer.

Authors:  Kevin R Krull; Kristina K Hardy; Lisa S Kahalley; Ilse Schuitema; Shelli R Kesler
Journal:  J Clin Oncol       Date:  2018-06-06       Impact factor: 44.544

6.  Prospective, longitudinal comparison of neurocognitive change in pediatric brain tumor patients treated with proton radiotherapy versus surgery only.

Authors:  Lisa S Kahalley; M Douglas Ris; Anita Mahajan; M Fatih Okcu; Murali Chintagumpala; Arnold C Paulino; William E Whitehead; Charles G Minard; Heather H Stancel; Jessica Orobio; Judy J Xue; Emily A Warren; David R Grosshans
Journal:  Neuro Oncol       Date:  2019-06-10       Impact factor: 12.300

7.  Evidence of high mortality in long term survivors of childhood medulloblastoma.

Authors:  Matthew S Ning; Stephanie M Perkins; Todd Dewees; Eric T Shinohara
Journal:  J Neurooncol       Date:  2015-01-04       Impact factor: 4.130

8.  Age-Dependent Cellular and Behavioral Deficits Induced by Molecularly Targeted Drugs Are Reversible.

Authors:  Joseph Scafidi; Jonathan Ritter; Brooke M Talbot; Jorge Edwards; Li-Jin Chew; Vittorio Gallo
Journal:  Cancer Res       Date:  2018-03-20       Impact factor: 12.701

9.  Effect of sensorineural hearing loss on neurocognitive and adaptive functioning in survivors of pediatric embryonal brain tumor.

Authors:  Andrew M Heitzer; Alexandra M Villagran; Kimberly Raghubar; Austin L Brown; Miranda L Camet; M Douglas Ris; Jenny H Hanning; M Fatih Okcu; Arnold C Paulino; Murali Chintagumpala; Lisa S Kahalley
Journal:  J Neurooncol       Date:  2019-11-28       Impact factor: 4.130

10.  Targeting Upstream Kinases of STAT3 in Human Medulloblastoma Cells.

Authors:  Jia Wei; Ling Ma; Chenglong Li; Christopher R Pierson; Jonathan L Finlay; Jiayuh Lin
Journal:  Curr Cancer Drug Targets       Date:  2019       Impact factor: 3.428

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.